Evidence map›Paper›PMID 36225927›Full record

ArticleFrontiers in immunology2022

Severity of SARS-CoV-2 infection is associated with high numbers of alveolar mast cells and their degranulation.

Olga Krysko, Joshua H Bourne, Elena Kondakova, Elena A Galova, Katharine Whitworth, Maddy L Newby, Claus Bachert, Harriet Hill, Max Crispin, Zania Stamataki and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Olga KryskoUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
Joshua H BourneInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Elena KondakovaInstitute of Biology and Biomedicine, Department of Basic and Medical Genetics, National Research Lobachevsky State University of Nizhniy Novgorod, Nizhniy Novgorod, Russia.
Elena A GalovaUniversity Clinic of Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Katharine WhitworthInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Maddy L NewbySchool of Biological Sciences, University of Southampton, Southampton, United Kingdom.
Claus BachertUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
Harriet HillInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Max CrispinSchool of Biological Sciences, University of Southampton, Southampton, United Kingdom.
Zania StamatakiInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Adam F CunninghamInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Matthew PughInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Abdullah O KhanInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Julie RayesInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Maria VedunovaInstitute of Biology and Biomedicine, Department of Basic and Medical Genetics, National Research Lobachevsky State University of Nizhniy Novgorod, Nizhniy Novgorod, Russia.
Dmitri V KryskoInstitute of Biology and Biomedicine, Department of Basic and Medical Genetics, National Research Lobachevsky State University of Nizhniy Novgorod, Nizhniy Novgorod, Russia.
Alexander BrillInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
University of Birmingham · GBGhent University · BEN. I. Lobachevsky State University of Nizhny Novgorod · RUUniversity of Southampton · GBPrivolzhsky Research Medical University · RU

Funding

British Heart Foundation FS/19/30/34173British Heart Foundation FS/IBSRF/20/25039Medical Research Council MR/N023706/1Medical Research Council MR/T001755/1MRF_ MRF-169-0001-F-STAM-C0826
6 · The paper itself

Abstract

Background: The systemic inflammatory response post-SARS-CoV-2 infection increases pro-inflammatory cytokine production, multi-organ damage, and mortality rates. Mast cells (MC) modulate thrombo-inflammatory disease progression ( Objective: To enhance our understanding of the contribution of MC and their proteases in SARS-CoV-2 infection and the pathogenesis of the disease, which might help to identify novel therapeutic targets. Methods: MC proteases chymase (CMA1), carboxypeptidase A3 (CPA3), and tryptase beta 2 (TPSB2), as well as cytokine levels, were measured in the serum of 60 patients with SARS-CoV-2 infection (30 moderate and 30 severe; severity of the disease assessed by chest CT) and 17 healthy controls by ELISA. MC number and degranulation were quantified by immunofluorescent staining for tryptase in lung autopsies of patients deceased from either SARS-CoV-2 infection or unrelated reasons (control). Immortalized human FcεR1 Results: The levels of all three proteases were increased in the serum of patients with COVID-19, and strongly correlated with clinical severity. The density of degranulated MC in COVID-19 lung autopsies was increased compared to control lungs. The total number of released granules and the number of granules per each MC were elevated and positively correlated with von Willebrand factor levels in the lung. SARS-CoV-2 or its viral proteins spike and nucleocapsid did not induce activation or degranulation of LUVA MC Conclusion: In this study, we demonstrate that SARS-CoV-2 is strongly associated with activation of MC, which likely occurs indirectly, driven by the inflammatory response. The results suggest that plasma MC protease levels could predict the disease course, and that severe COVID-19 patients might benefit from including MC-stabilizing drugs in the treatment scheme.

Indexed as

COVID-19CarboxypeptidasesChymasesCytokinesHumansMast CellsSARS-CoV-2TryptasesViral Proteinsvon Willebrand FactorCarboxypeptidasesChymasesCytokinesTryptasesViral Proteinsvon Willebrand FactorCOVID-19LUVA cellsmast cellsproteasevon Willebrand factor

Identifiers

PMID36225927
PMCPMC9548604
OpenAlexW4297154512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.